Nuvalent Drug Patent Portfolio
Nuvalent owns 1 orange book drug protected by 4 US patents Given below is the list of Nuvalent's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12043626 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds | 30 Sep, 2042 | Active |
| US12630560 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds | 30 Sep, 2042 | Active |
| US11542278 | 05 May, 2041 | Active | |
| US12054498 | Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents | 05 May, 2041 | Active |
Nuvalent's Family Patents
Nuvalent Drug List
Given below is the complete list of Nuvalent's drugs and the patents protecting them.
1. Jideytro
Jideytro is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12043626 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
30 Sep, 2042
(16 years from now)
| Active |
| US12630560 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds |
30 Sep, 2042
(16 years from now)
| Active |
| US11542278 |
05 May, 2041
(14 years from now)
| Active | |
| US12054498 | Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents |
05 May, 2041
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jideytro's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List